See more : Welcia Holdings Co., Ltd. (WLCGF) Income Statement Analysis – Financial Results
Complete financial analysis of Fulgent Genetics, Inc. (FLGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fulgent Genetics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Southern ITS International, Inc. (SITS) Income Statement Analysis – Financial Results
- China Shuifa Singyes Energy Holdings Limited (0750.HK) Income Statement Analysis – Financial Results
- V.S. Industry Berhad (6963.KL) Income Statement Analysis – Financial Results
- Givot Olam Oil Exploration-Limited Partnership(1993) (GOOXF) Income Statement Analysis – Financial Results
- Fattal Holdings (1998) Ltd (FATLF) Income Statement Analysis – Financial Results
Fulgent Genetics, Inc. (FLGT)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.fulgentgenetics.com
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2001 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 289.21M | 618.97M | 992.58M | 421.71M | 32.53M | 21.36M | 18.73M | 18.28M | 9.58M | 1.28M | 0.00 |
Cost of Revenue | 184.76M | 252.07M | 215.53M | 89.81M | 14.11M | 10.69M | 8.55M | 6.72M | 5.07M | 936.00K | 0.00 |
Gross Profit | 104.46M | 366.90M | 777.05M | 331.91M | 18.42M | 10.67M | 10.18M | 11.56M | 4.51M | 342.00K | 0.00 |
Gross Profit Ratio | 36.12% | 59.28% | 78.29% | 78.70% | 56.63% | 49.94% | 54.35% | 63.22% | 47.07% | 26.76% | 0.00% |
Research & Development | 41.44M | 28.91M | 24.22M | 11.58M | 6.54M | 5.53M | 4.22M | 3.56M | 4.43M | 521.00K | 0.00 |
General & Administrative | 89.00M | 111.07M | 50.73M | 15.22M | 6.41M | 5.54M | 5.13M | 4.61M | 2.42M | 230.00K | 0.00 |
Selling & Marketing | 41.47M | 38.92M | 24.44M | 14.95M | 5.90M | 4.65M | 4.22M | 2.47M | 2.67M | 581.00K | 0.00 |
SG&A | 130.47M | 149.99M | 75.17M | 30.17M | 12.31M | 10.19M | 9.36M | 7.08M | 5.09M | 811.00K | 0.00 |
Other Expenses | 0.00 | 6.50M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.34M |
Operating Expenses | 171.91M | 185.40M | 101.10M | 41.75M | 18.85M | 15.72M | 13.58M | 10.64M | 9.52M | 1.33M | 104.34M |
Cost & Expenses | 364.51M | 437.47M | 316.63M | 131.55M | 32.96M | 26.41M | 22.13M | 17.36M | 14.59M | 2.27M | 104.34M |
Interest Income | 21.44M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | 1.00K | 27.00K | 0.00 | 0.00 |
Interest Expense | 0.00 | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.39M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 26.14M | 36.91M | 12.16M | 3.37M | 2.52M | 2.16M | 1.73M | 1.17M | 575.00K | 196.00K | 0.00 |
EBITDA | -46.55M | 221.59M | 675.95M | 290.16M | 1.68M | -2.91M | -1.75M | 2.09M | -4.44M | -794.00K | 104.34M |
EBITDA Ratio | -16.10% | 30.85% | 68.27% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -46.33% | -62.13% | 0.00% |
Operating Income | -72.70M | 178.53M | 675.95M | 290.16M | -428.00K | -5.06M | -3.40M | 919.00K | -5.01M | -990.00K | 104.34M |
Operating Income Ratio | -25.14% | 28.84% | 68.10% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -52.34% | -77.46% | 0.00% |
Total Other Income/Expenses | -101.39M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | -5.39M | 27.00K | 0.00 | 0.00 |
Income Before Tax | -174.09M | 184.03M | 677.30M | 291.68M | 409.00K | -4.62M | -2.92M | -4.47M | -4.99M | -990.00K | 104.34M |
Income Before Tax Ratio | -60.19% | 29.73% | 68.24% | 69.17% | 1.26% | -21.65% | -15.58% | -24.45% | -52.06% | -77.46% | 0.00% |
Income Tax Expense | 1.15M | 42.10M | 174.80M | 72.53M | 43.00K | -1.07M | -768.00K | 920.00K | 3.33M | 3.29M | 0.00 |
Net Income | -167.83M | 143.40M | 507.36M | 214.31M | 366.00K | -4.49M | -2.66M | -5.39M | -8.31M | -4.28M | 104.34M |
Net Income Ratio | -58.03% | 23.17% | 51.12% | 50.82% | 1.13% | -21.02% | -14.21% | -29.48% | -86.82% | -335.13% | 0.00% |
EPS | -5.63 | 4.76 | 17.13 | 9.64 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.48 |
EPS Diluted | -5.63 | 4.63 | 16.26 | 9.09 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.34 |
Weighted Avg Shares Out | 29.78M | 30.10M | 29.41M | 22.69M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 29.96M |
Weighted Avg Shares Out (Dil) | 29.78M | 30.96M | 30.98M | 24.06M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 31.20M |
Fulgent Genetics to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday February 23, 2022
Fullgent Genetics (FLGT) Gains As Market Dips: What You Should Know
This Sector is 13% of the Stock Market and Has Lifelong Potential
The Most Important Chart for Fulgent Genetics Shareholders
Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy
Why Fulgent Genetics Stock Plummeted 36.5% Last Month
4 Stocks With High Net Income Ratio to Scoop Up
New Strong Buy Stocks for January 26th
3 Smallcaps That Got Flushed With The Market
Fulgent Genetics: Sell Volatility
Source: https://incomestatements.info
Category: Stock Reports